Clinical and molecular evolution in patients treated with ECP and CHOP
| Patient . | Treatment . | Clinical course . | Evolution of Sézary cells . | Evolution of relative frequency of clone . |
|---|---|---|---|---|
| V | ECP | Improvement (before histologic transformation) | 7/2% | 9/0/0.5% |
| V | CHOP | Progressive worsening | 2/0% | 0.5/6% |
| Sa | ECP | Stable, then worsening | 10/31% | 9/30% |
| Vd | ECP | Progressive worsening | 42/26% | 9/18% |
| Bra | ECP | Improvement, then worsening | 16/19% | then 84/8/37/20% |
| Ciz | ECP | Partial efficiency, then worsening | 7/5% | Fluctuations 18/20% |
| Sy | ECP | Complete remission | 27/0% | 16% disappearance of the peak |
| Sv | ECP | Worsening | — | Fluctuations 18/10/41/6% |
| R | ECP | Worsening | 2/4% | then 20/2/8.5% |
| D | CHOP | Partial remission | 14/0% | then 43/7/16% |
| Patient . | Treatment . | Clinical course . | Evolution of Sézary cells . | Evolution of relative frequency of clone . |
|---|---|---|---|---|
| V | ECP | Improvement (before histologic transformation) | 7/2% | 9/0/0.5% |
| V | CHOP | Progressive worsening | 2/0% | 0.5/6% |
| Sa | ECP | Stable, then worsening | 10/31% | 9/30% |
| Vd | ECP | Progressive worsening | 42/26% | 9/18% |
| Bra | ECP | Improvement, then worsening | 16/19% | then 84/8/37/20% |
| Ciz | ECP | Partial efficiency, then worsening | 7/5% | Fluctuations 18/20% |
| Sy | ECP | Complete remission | 27/0% | 16% disappearance of the peak |
| Sv | ECP | Worsening | — | Fluctuations 18/10/41/6% |
| R | ECP | Worsening | 2/4% | then 20/2/8.5% |
| D | CHOP | Partial remission | 14/0% | then 43/7/16% |